A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration

Shashikant Sharma1, Mubeen Khan1, Alok Chaturvedi1
1Medical Services, Intas Pharmaceuticals Ltd., Ahmedabad, India

Tóm tắt

Từ khóa


Tài liệu tham khảo

Alexandru MR, Alexandra NM. Wet age related macular degeneration management and follow-up. Rom J Ophthalmol. 2016;1:9–13.

Ayoub T, Patel N. Age-related macular degeneration. J R Soc Med. 2009;2:56–61.

Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;4:564–72.

Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.

Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2013;9:1860–70.

Topal T, Kar T, Yıldırım Y, et al. Evaluation of aflibercept treatment responses in eyes with bevacizumab/ranibizumab-resistant wet age-related macular degeneration. Turk J Ophthalmol. 2017;3:133–7.

Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012;1:26–39.

Cohen SY, Creuzot-Garcher C, Darmon J, et al. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol. 2007;9:1173–6.

Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;11:1640–2.

Thapa R, Bajimaya S, Paudyal G, et al. Prevalence of and risk factors for age-related macular degeneration in Nepal: the Bhaktapur Retina Study. Clin Ophthalmol. 2017;11:963–72.

Woo JH, Sanjay S, Au Eong KG. The epidemiology of age-related macular degeneration in the Indian subcontinent. Acta Ophthalmol. 2009;3:262–9.

Sivaprasad S, Hykin P. What is new in the management of wet age-related macular degeneration? Br Med Bull. 2013;1:201–11.

Regillo CD. Anti-VEGF maintenance therapy for neovascular AMD. Retina Today. 2014;63–67.

Jaki Mekjavic P, Zaletel Benda P. Outcome of 5-year treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF using “treat and extend” regimen. Front Med (Lausanne). 2018;5:125.

Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;14:1419–31.

Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;14:1432–44.

Intas Pharmaceuticals Limited. Intas launches RAZUMAB, globally the first biosimilar to Lucentis® (ranibizumab). https://www.prnewswire.com/in/news-releases/intas-launches-razumab-globally-the-first-biosimilar-to-lucentis-ranibizumab-508383021.html. Accessed 12 Jul 2019.

Sameera VV, Ayachit A, Joshi S, Guruprasad AS. Safety and efficacy of Razumab—the new biosimilar in India: our experience. Kerala J Ophthalmol. 2016;28:180.

Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-life clinical effectiveness of Razumab® (the world’s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;241:24–31.

Sharma S, RE-ENACT Study Investigators Group, Khan MA, Chaturvedi A. Real-life clinical effectiveness of Razumab® (world’s first biosimilar ranibizumab) in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a retrospective pooled analysis. Int J Ophthalmol Eye Res. 2018;6(4):377–83.

Sharma S, RE-ENACT Study Investigators Group, Khan MA, Chaturvedi A. Real life clinical effectiveness of Razumab® (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a subgroup analysis of pooled retrospective RE-ENACT study. Int J Ophthalmol Eye Res. 2018;6(2):368–73.

Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond). 2016;2:270–86.

Ferro Desideri L, Barra F, Ferrero S, Traverso CE, Nicolo M. Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Expert Opin Biol Ther. 2019;1–17.

Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2007;8:1199–206 (discussion 1207–9).

Qi H-J, Li X-X, Zhang J-Y, Zhao M-W. Efficacy and safety of ranibizumab for wet age-related macular degeneration in Chinese patients. Int J Ophthalmol. 2017;1:91–7.

Małgorzata F, Stankiewicz A. Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. Med Sci Monit. 2011;9:CR485–90.

Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol. 2010;3:292–6.

Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018;8:1464–77.

Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mones J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;1:57–65.

Sharei V, Hohn F, Kohler T, Hattenbach LO, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;1:174–9.

Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;9:1802–10.

Sharma S, Toth CA, Daniel E, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;4:865–75.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;5:723–34.

Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (an AOS thesis). Trans Am Ophthalmol Soc. 2009:311–324.